Idioma:

The treatment of recurrence in children with acute lymphatic leukemia. Current results and various developments

Kaspers, G J ; Pieters, R ; Klumper, E ; de Waal, F C ; Veerman, A J

Tijdschrift voor kindergeneeskunde, 1993-02, Vol.61 (1), p.1-7

Netherlands

Sem texto completo

Citações Citado por

Enviar para

Título:
The treatment of recurrence in children with acute lymphatic leukemia. Current results and various developments
Autor: Kaspers, G J ; Pieters, R ; Klumper, E ; de Waal, F C ; Veerman, A J
Assuntos: Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bone Marrow Transplantation ; Child ; Child, Preschool ; Female ; Growth Substances - therapeutic use ; Humans ; Immunotherapy - methods ; Infant ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - physiopathology ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Prognosis ; Recurrence ; Remission Induction ; Tumor Stem Cell Assay
É parte de: Tijdschrift voor kindergeneeskunde, 1993-02, Vol.61 (1), p.1-7
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: The results of current treatment of relapsed childhood acute lymphoblastic leukemia (ALL) are discussed, together with some recent developments which (might) influence such treatment. At present more than 95% of children with ALL will achieve a complete remission (CR), and +/- 70% will remain in CR. Nevertheless, 20-30% of the patients suffer a relapse, which implies a less favorable prognosis. However, after intensive treatment a part of these patients will have a prolonged second complete remission: 30-50% of children with a late relapse and 0-20% of children with an early relapse. It is important to prevent the occurrence of a relapse. The identification at diagnosis of patients at high risk for a relapse, and a subsequent more specific and more intensive treatment of these patients might contribute to that goal. Well-known risk factors are briefly mentioned, factors of which the prognostic significances is therapy-dependent. In addition, the treatment of relapsed ALL needs further improvement. Some alternatives to achieve this goal are discussed, including the role of in vitro cytostatic drug resistance testing.
Editor: Netherlands
Idioma: Holandês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The treatment of recurrence in children with acute lymphatic leukemia. Current results and various developments

Kaspers, G J ; Pieters, R ; Klumper, E ; de Waal, F C ; Veerman, A J

Netherlands

Buscando em bases de dados remotas. Favor aguardar.